U.S. markets closed

Exagen Inc. (E08A.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
1.8000-0.0400 (-2.17%)
At close: 08:17AM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8400
Bid1.8600 x N/A
Ask1.9300 x N/A
Day's Range1.8000 - 1.8000
52 Week Range1.3300 - 3.1800
Avg. Volume33
Market Cap31.851M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-1.7200
Earnings DateMar 18, 2024 - Mar 22, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for E08A.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Zacks

      Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock

      Exagen Inc. (XGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

    • GlobeNewswire

      Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

      CARLSBAD, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 13-14, 2024 in Snowbird, Utah. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will be participating in one-on-one meetings with investors during the event; meetin

    • GlobeNewswire

      Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

      CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance. Select Preliminary Unaudited Financial Results Record AVISE® CTD testing volume of approximately 137,000 units delivered during the year ended December 31, 2023.Cash balance of $36.5 million as of December 31,